BCL2 and neuroblastoma: We found that in both SCLC and neuroblastoma, cell lines with higher NE scores were more resistant to drugs that target MEK, mTOR, XIAP, LCK, HSP90, and Abl but were more sensitive to BCL inhibitors, which inhibit anti-apoptotic B-cell lymphoma-2 (Bcl-2) family of proteins.